ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,452.17
0.84%
Dow Jones
39,387.76
0.85%
Gold vs US Dollar
2,375.285
1.21%
Brent Oil
84.245
0.35%
Bitcoin
63,003.76
-0.07%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Theseus Pharmaceuticals Inc (THRX)

  7. Theseus Pharmaceuticals Inc (THRX) News

Theseus Pharmaceuticals (THRX)

Theseus Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:THRX
DateTimeSourceHeadlineSymbolCompany
26/02/202414:00Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:THRXTheseus Pharmaceuticals Inc
16/02/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:THRXTheseus Pharmaceuticals Inc
14/02/202421:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:THRXTheseus Pharmaceuticals Inc
14/02/202419:26Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:THRXTheseus Pharmaceuticals Inc
14/02/202419:24Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:THRXTheseus Pharmaceuticals Inc
14/02/202419:22Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:THRXTheseus Pharmaceuticals Inc
14/02/202415:44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:THRXTheseus Pharmaceuticals Inc
14/02/202415:35Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
14/02/202413:30PR Newswire (US)Theseus Pharmaceuticals Announces Closing of Tender OfferNASDAQ:THRXTheseus Pharmaceuticals Inc
13/02/202417:36Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
07/02/202422:21Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
07/02/202422:15Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
30/01/202413:52Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
30/01/202413:23Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
30/01/202413:00Business WireConcentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus PharmaceuticalsNASDAQ:THRXTheseus Pharmaceuticals Inc
10/01/202414:47Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:THRXTheseus Pharmaceuticals Inc
10/01/202413:51Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:THRXTheseus Pharmaceuticals Inc
22/12/202311:52Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:THRXTheseus Pharmaceuticals Inc
22/12/202311:36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:THRXTheseus Pharmaceuticals Inc
22/12/202311:30PR Newswire (US)Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value RightNASDAQ:THRXTheseus Pharmaceuticals Inc
04/12/202311:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:THRXTheseus Pharmaceuticals Inc
27/11/202311:37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:THRXTheseus Pharmaceuticals Inc
27/11/202311:30PR Newswire (US)Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLCNASDAQ:THRXTheseus Pharmaceuticals Inc
24/11/202321:23Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
17/11/202321:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:THRXTheseus Pharmaceuticals Inc
15/11/202312:00Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:THRXTheseus Pharmaceuticals Inc
13/11/202321:05PR Newswire (US)Theseus Pharmaceuticals Announces Process to Explore Strategic AlternativesNASDAQ:THRXTheseus Pharmaceuticals Inc
07/11/202321:05PR Newswire (US)Theseus Pharmaceuticals to Participate in the Stifel 2023 Healthcare ConferenceNASDAQ:THRXTheseus Pharmaceuticals Inc
07/11/202321:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:THRXTheseus Pharmaceuticals Inc
31/10/202320:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:THRXTheseus Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:THRX

Your Recent History

LSE
SYME
Supply@me Capital
LSE
POS
Plexus
LSE
TERN
Tern
LSE
SFOR
S4 Capital
LSE
PET
Petrel Resources
LSE
AAZ
Anglo Asian Mining
LSE
CHLL
Chill Brands
LSE
ITV
Itv
LSE
TXP
Touchstone Exploration
LSE
POLX
Polarean Imaging
LSE
GOLD
LSE
GDR
Genedrive
LSE
BOO
Boohoo
LSE
AGL
Angle
LSE
TPL
Tethys
LSE
LLOY
Lloyds Banking
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved